

This data dictionary is for the NCT00046930-D1 dataset. These data are presented in PMID 37407550, which is a correction to PMID 36151075.

Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for deidentification purposes or have undergone further data cleaning).

Note: For all variables, the notation “NA” refers to data missing/unknown

Variables in this dataset that contain limited high-dimensional “omic” data are provided in addition to the clinical data in an “as-is” state without all the same quality-control procedures that are performed on the clinical data by the NCTN/NCORP Data Archive. It may not be possible to fully reproduce the results of the genomic analyses included in the publication. For example, the “omic” data provided may be a subset of the data used in the publication or may not reflect certain aspects of the data processing.

Variable	Description/coding	Data type	Note
ID	unique patient identifier	number	
age	age in years (at study entry). Patients 90 or older are listed as >90.	number	
aml10prog	Cytogenetics: NA='Missing' 2='Favorable' 3='Indeterminate' 4='Intermediate' 5='Unfavorable'	number	Defined based on criteria at the time of the clinical study (Cripe, et al. Blood 2010)
CR	Complete remission status after induction treatment: 1=CR 0='non-CR'	number	
dfs_cr_cns	Disease-Free Survival indicator: 1=event 0=censor	number	Defined at time of clinical study report (Cripe, et al. Blood 2010)
dfs_cr_mos	Disease-Free Survival (months)	number	Defined at time of clinical study report (Cripe, et al. Blood 2010)
efs_cns	Event-Free Survival indicator: 1=event 0=censor	number	Defined at time of clinical study report (Cripe, et al. Blood 2010)
efs_mos1	Event-Free Survival (months)	number	Defined at time of clinical study report (Cripe, et al. Blood 2010)
ELN2017_classification	ELN2017 classification: 1 = good, 2 = intermediate, 3 = poor, 4 = unknown	number	European Leukemia Net (ELN) risk classification as defined in Döhner, et al. Blood 2017.
Exome	Exome capture performed on subject-matched tumor/normal specimens: 1=performed 0 = not performed	number	Included in Rapaport, Seier and Neelamraju et al. (Blood Cancer Journal 2022 and 2023)

G1_G6_prognosticGroups	G1-G6 prognostic group annotation	number	Included in Rapaport, Seier and Neelamraju et al. (Blood Cancer Journal 2022 and 2023)
HGB_RS	Hemoglobin (g/dl)	number	
os_mos1	Overall Survival (months)	number	Defined at time of clinical study report (Cripe, et al. Blood 2010)
PLT_RS	Peripheral platelet count (/mm3)(x1000)	number	
sex	sex (1=male; 2=female)	number	
surv	survival status: 1=death 0=alive	number	Defined at time of clinical study report (Cripe, et al. Blood 2010)
trt	induction treatment: 1='Zosuquidar' 2='Placebo'	number	
type_oc_new	Disease type: 1='De novo AML' 2='missing/unknown 3='RAEB' 4='RAEB-t' 5='secondary AML'	number	Defined based on criteria at the time of the clinical study (Cripe, et al. Blood 2010)
WBC_RS	Peripheral WBC count (/mm3)(x1000)	number	
FollowUP_spec_ID	unique patient identifier for patient-matched relapsed specimens	character	

#### References:

Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Luger S, Tallman MS. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. *Blood*. 2010 Nov 18;116(20):4077-85. doi: 10.1182/blood-2010-04-277269. Epub 2010 Aug 17. PMID: 20716770; PMCID: PMC2993615.

Rapaport F, Seier K, Neelamraju Y, Hassane D, Baslan T, Gildea DT, Haddox S, Lee T, Murdock HM, Sheridan C, Thurmond A, Wang L, Carroll M, Cripe LD, Fernandez H, Mason CE, Paietta E, Roboz GJ, Sun Z, Tallman MS, Zhang Y, Gönen M, Levine R, Melnick AM, Kleppe M, Garrett-Bakelman FE. Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. *Blood Cancer J*. 2022 Sep 23;12(9):137. doi: 10.1038/s41408-022-00736-z. PMID: 36151075; PMCID: PMC9508258. Erratum in: *Blood Cancer J*. 2023 Jul 6;13(1):103. PMID: 37407550; PMCID: PMC10322919.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. PMID: 27895058; PMCID: PMC5291965.